Kornimate/medical-research-clean huggingface dataset:
compariing a bioactive resin material used as a fissure sealant to a conventional resin

Conditions: Demineralization, Tooth; Demineralization, Fissure; Non-Cavitated Caries

Summary: the aim of this study is to investigate the retention, marginal integrity and potential to prevent lesion progression of a bioactive resin material compared to a conventional resin-based flowable composite during management of initial carious lesion in adult population over an 18 months period.

bio-active resin materials aim to possess the mechanical properties of resin materials in terms of higher wear resistance and dimensional stability over time. they also aim to mimic the biological activity of glass ionomers in terms of ion recharge and release. these new bio-active resin materials, with their lower particle size and better adaptability and polishability, might offer a substantial addition as fissure sealants if they fulfil the requisities satisfactory mechanical properties of resins and of ion recharge and release of glass ionomers. the study will be conducted on demineralized fissures of permanent molars by application of a newly introduced giomer in one group while the other group will recieve a conventional resin material where they will be assessed for retention, marginal integrity and caries progression.

Eligibility criteria:
inclusion criteria: * patients with good oral hygiene * co-operative patients with initially demineralized fissures in permanent molars of the maxilla or mandible exclusion criteria: * medical problems or pregnancy * lack of patient's approval and compliance * presence of abnormal oral, medical, or mental condition * known allergy of resin-based materials * previous placements of sealants or restorations * bruxism or mal-occlusion
study of inhaled rns60 in combination with budesonide to treat mild to moderate asthma

Conditions: Asthma

Summary: the purpose of this study is to determine whether rns60, in combination with budesonide, is safe in mild to moderate asthmatics when taken by nebulization over a 28-day period, compared to a 28-day control period.


Eligibility criteria:
inclusion criteria: * male or female non-smokers, aged between 18 and 65 years. * clinical diagnosis of mild to moderate asthma meeting nhlbi 2007 guidelines as outlined in appendix a. * subjects who have a currently prescribed inhaled corticosteroid medication to treat asthma, alone or in combination with other medications, with usage of 1 month (≥ 95% compliance) or more on the inhaled corticosteroid treatment. * normal 12-lead ecg at screening. * normal single view chest x-ray at screening. * men and women of reproductive potential who commit to use adequate contraception during the study and for 1 month following the last day of treatment (day 57). * women of childbearing potential who have a negative pregnancy test (serum hcg) at the time of study entry, and again on day 22. * subjects, or their legal guardians, must be capable of understanding the purpose and risks of the study and provide written, voluntary, informed consent. exclusion criteria: * chronic or acute disease that might interfere with the evaluation of rns60. * pregnancy, intent to become pregnant, or breastfeeding. * current or prior malignancies (excluding non-melanoma skin carcinoma or in situ carcinoma of the cervix that has been adequately treated). * positive viral serology test for human immunodeficiency virus (hiv-1), hbsag and hepatitis c antibody. * positive urine drug screen (uds) for drugs of abuse including alcohol and cotinine at the time of study entry and again on day 22. * infections that require intravenous antibiotic therapy. * significant organ dysfunction, including cardiac, renal, liver, central nervous system, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine ≥ 1.6 mg/dl; alt or ast ≥ 1.5x the upper limit of normal), history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to study entry. * treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study entry. * treatment with any investigational drugs, therapies, or medical devices within 4 weeks prior to study entry. * any use of antidepressants or other psychiatric medicine within 4 weeks prior to study entry and/or during the study treatment period. * use of any over-the-counter asthma treatments, including primatene mist, during the 8-week active study period.
molecular fluorescence endoscopy in patients with familial adenomatous polyposis, using bevacizumab-irdye800cw

Conditions: Adenomatous Polyposis Coli

Summary: there is a need for better visualization of polyps during surveillance endoscopy in patients with hereditary colon cancer syndromes like familial adenomatous polyposis (fap) and lynch syndrome (ls), to improve the adenoma detection rate. optical molecular imaging of adenoma associated biomarkers is a promising technique to accommodate this need. the biomarker vascular endothelial growth factor (vegf) is overexpressed in adenomatous colon tissue versus normal tissue and has proven to be a valid target for molecular imaging. the university medical center groningen (umcg) developed a fluorescent tracer by labeling the vegf-targeting humanized monoclonal antibody bevacizumab, currently used in anti-cancer therapy, with the fluorescent dye irdye800cw. the investigators hypothesize that when bevacizumab-irdye800cw is administered to patients, it accumulates in vegf expressing adenomas, enabling adenoma visualization using a newly developed near-infrared (nir) fluorescence endoscopy platform (nl43407.042.13). this hypothesis will be tested in this feasibility study, next to the determination of the optimal tracer dose.


Eligibility criteria:
inclusion criteria: * patients with genetically or clinically proven familial adenomatous polyposis. genetically proven: adenomatous polyposis coli (apc)-mutation identified. clinically proven: more than 100 colorectal polyps at diagnosis * age 18 to 70 years * written informed consent * adequate potential for follow-up exclusion criteria: * medical or psychiatric conditions that compromise the patient's ability to give informed consent * proctocolectomy * mutyh mutation * concurrent uncontrolled medical conditions * pregnant or lactating women. documentation of a negative pregnancy test must be available for woman of childbearing potential. woman of childbearing potential are pre-menopausal women with intact reproductive organs and women less than two years after menopause.

Keywords: optical imaging fluorescence endoscopy near infrared fluorescence familial adenomatous polyposis irdye800cw vascular endothelial growth factor a gastrointestinal endoscopy
the characterization of blood volumes of commercially available lancing devices

Conditions: Diabetes

Summary: characterize expressed blood volume ≥1μl across representative, commercially available lancing device systems using finger sticks.

primary objective: • characterize expressed blood volume ≥1μl across representative, commercially available lancing device systems using finger sticks. secondary objectives: the following characterizations will be performed in the data analysis within each device and across each device: * correlation of subject pain response to blood volume collected; * proportion of subjects that produce sufficient blood to fill a 1µl test strip; * proportion of subjects that generate ≥1µl blood volume; * proportion of subjects who generate multiple- times the blood volume needed to fill a 1µl test strip * proportion of subjects who generate multiple- times ≥1µl of blood volume * proportion of subjects that produce on average (≥1µl) of blood volume on 1st attempt * proportion of subjects that produce on average (≥1µl) of blood volume on their first and second lancing attempt

Eligibility criteria:
inclusion criteria: * must be diagnosed with type 1 or type 2 diabetes for one (1) or more year(s). * must be currently self-monitoring blood glucose levels for at least 6 months. * must self-test at least 2 times daily. * must be between the ages of 18 and 75 to participate. * subjects must be able to perform all tasks required in this protocol. * subjects must be willing to complete all study procedures. * subjects must be able to speak, read and understand english and understand the informed consent document. exclusion criteria: * subjects with neuropathy or any other nerve damage in the hand or fingers (this will be discovered through the monofilament test) * subjects who are taking prescription anti-coagulants or more than one full aspirin per day during the past week or have clotting problems that may prolong bleeding (persons taking plavix or a daily low dose aspirin will not be excluded but this will be recorded). * subjects taking pain relievers within 24 hours. * subjects with hemophilia or any other bleeding disorder. * subjects with infection with a blood borne pathogen (e.g., hiv, hepatitis). * subjects having a condition such as a cognitive disorder, which in the opinion of the investigator would put the person at risk or seriously compromise the integrity of the study (pi will sign case report form if subject is excluded). * subjects working for facet, lifescan inc., or a competitive company. * subjects with missing digits. * subjects who are pregnant or nursing. * subjects on chemotherapy.
long-term assessment of organ functions among survivors of severe acute respiratory syndrome

Conditions: SARS Virus; Long-Term Survivors

Summary: sars-cov has caused severe epidemic respiratory disease in human populations. by july 2003, a total of 8,096 probable cases of sars had been reported including 774 deaths in 27 countries, around one-third of which were health care workers (hcws). previous studies have been reported about long-term impacts of sars infection, including lung function deficiency, steroid-induced osteonecrosis, reduced exercise capacity, and impairment in health-related quality of life (hrqol). hcws, especially nurses, have been reported to experience greater psychological distress, particularly increased levels of posttraumatic stress symptomatology (ptss). but the very complex impacts of this fatal infection on hcws have not been fully elucidated. it is thus important to follow these occupational patients to detect and manage multi-organ sequelae and functional impairment.


Eligibility criteria:
inclusion criteria: * health care workers who were working at peking university people's hospital during the sars epidemic in 2002-2003 exclusion criteria: * refusal to continue the study
use of lapis judaicus to dissolve kidney stones

Conditions: Kidney Calculi

Summary: the investigators will investigate the safety and effectiveness of an iranian traditional medicine regarding its ability to dissolve existing kidney stones. calcium stone formers will be recruited for a 12 week trial. each subject will receive lapis judaicus or placebo in random order. end points are changes in urinary chemistries and stone burden by ultra sonography / ct scan. it will be used in proven calcium stone forming adults who are not pregnant. this phase is a double blind, randomized, placebo controlled entry, first and 12 week 24 hour urine supersaturations, ph and sodium determinations will be collected. entry and final stone quantification ultra sonography / ct scan will be performed. end points will be changes in urine chemistry/supersaturation and stone quantitative stone volume.


Eligibility criteria:
inclusion criteria: * age 18 or over * mentally competent * medically effective birth control if fertile female * history of calcium containing stone and current quantifiable stone * able to comply with protocol exclusion criteria: * prisoner * pregnant * ckd

Keywords: kidney calculi iranian traditional medicine lapis judaicus
fstl1 and ppcs on pediatric within ldlt:a prospective cohort analysis

Conditions: Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS); Pulmonary Complication; Liver Transplant; Complications

Summary: the goal of this observational study is to identify the association between fstl1 elevation and acute lung injury (ali) after pediatric liver transplantation.the main questions it aims to answer what the risk factors are for ali in children and to evaluate the predictive value for the development of ali.participants will be divided into non-ali group and ali group according to whether they had ali in a week after liver transplantation.researchers will compare the difference between the two groups and use multivariate logistic regression analysis to screen the risk factors of ali, and receiver operating characteristic(roc) curve was used to evaluate the predictive efficacy of risk factors.

postoperative pulmonary complications(ppc) are complicated diseases with high morbidity and mortality for pediatric after living donor liver transplant (ldlt), acute lung injury(ali) after ldlt is a common and complex pulmonary complication, it is leading causes of disability and death,both in the acute and long-term postoperative period, the identification of effective prediction model involved in ali is urgent and highly demanded.in order to observe the effect of follistim like protein 1(fstl1) on the incidence of ali who underwent ldlt, and explore the related mechanism, the investigators aim to collect more than 400 infant patients underwent ldlt from may 2023 to december 2023 in our single-center prospective study. basic clinical data of children were recorded, including age, gender, alanine aminotransferase (alt), aspartate aminotransferase (ast), international normalized ratio (inr), childhood end-stage liver disease score (peld) and other indicators.the expression levels of serum fstl1 were recorded immediately after induction of anesthesia (t1), 10 minutes at anhepatic stage (t2), 30 minutes at new hepatic stage (t3) and immediately after abdominal closure (t4). murray score was used to determine whether ali occurred one week after ldlt, and the children were divided into non-ali group and ali group. postoperative mechanical ventilation time, icu stay time, total length of hospital stay and mortality during hospitalization are recorded. the primary outcome utilised a regression approach to adjust for potential confounders associated with ali and fstl1. multivariate logistic regression analysis was used to screen the risk factors of ali, and roc curve was used to evaluate the predictive efficacy of risk factors.

Eligibility criteria:
inclusion criteria: * patient was diagnosed with biliary atresia * american society of anesthesiologists physical status ⅱ-ⅲ exclusion criteria: * secondary liver transplantation or other important organ injury before surgery * present with congenital airway or respiratory malformation * acute respiratory infection or respiratory insufficiency was present within 1 month before surgery

Keywords: follistatins-like protein 1 pulmonary complication living donor liver transplantation
remodeling the left ventricle with atrial modulated pacing

Conditions: Heart Failure

Summary: new therapy tested in heart failure with preserved ejection fraction (hfpef) patients with approved indications for pacing to determine if elevated pacing therapy is tolerated and whether there is a signal for efficacy.


Eligibility criteria:
inclusion criteria: * subject has had a market released dual chamber medtronic pacemaker with a sleep function for at least 3 months * subject is stable on current medications * subject has dyspnea with exertion or diagnosed as new york heart association (nyha) class ii or iii heart failure * subject has had a prior echo in past 6 months with: ejection fraction (ef) ≥ 50% and diastolic volume \<80 ml/m² * subject has evidence of hypertrophy (indexed to body surface area: men 115 g/m², women 95 g/m² or indexed to height: men 49.2 g/m2.7, women 46.7 g/m2.7) or relative wall thickness \>0.42, or wall thickness\>1.2cm (posterior wall) * subject is willing to sign and date the study informed consent form (ic form) - subject is 18 years of age or older, or of legal age to give informed consent per local law * subject is expected to remain available for follow-up visits exclusion criteria: * subject has permanent atrial fibrillation (af) or af noted on baseline interrogation rhythm strip * subject has uncontrolled bp; (systolic pressure needs to be \>100 mmhg and \<160 mmhg on medications) * subject has severe stenosis of the aortic or mitral valve, defined as valve area ≤1.0 cm² or severe regurgitation of the aortic or mitral valve * subject has symptomatic chronic obstructive pulmonary disease (copd) requiring oxygen * subject's pacemaker has less than 6 months of pacemaker battery life * subject had an aortic valve replacement (surgical or tavr) procedure less than 9 months prior to enrollment * subject's programmed upper rate limit is less than 100 bpm because of concerns of elevated pacing * subject is unable or unwilling to perform the 6 minute walk test at all scheduled study visits * subject is currently enrolled or planning to enroll in a potentially confounding trial during the course of the study (co-enrollment in concurrent studies is only allowed when documented pre-approval is obtained from the medtronic study manager) * subject is pregnant * subject meets any exclusion criteria required by local law * subject's life expectancy is less than 12 weeks * subject with medical condition that precludes the patient from participation in the opinion of the investigator * subject has known coronary disease with class ii angina
a study to assess the safety and pharmacokinetics of an inhibitor of parp in combination with dacarbazine

Conditions: Melanoma Neoplasms

Summary: this is a phase i, open-label, dose-escalating, study of the safety and tolerability of ku-0059436 in combination with dtic in the treatment of patients with advanced melanoma who have not previously received systemic cytotoxic chemotherapy.


Eligibility criteria:
inclusion criteria: * patients must have: 1. unresectable stage 3 or stage 4 cutaneous melanoma or unknown primary melanoma with metastases. 2. histological or cytological confirmation of melanoma. histological confirmation of melanoma from the primary site will suffice, unless the primary site is unknown. exclusion criteria: * previous treatment with cytotoxic chemotherapy for advanced melanoma, apart from treatment for melanoma with isolated limb perfusion. * radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or use of other investigational agents within 4 weeks prior to trial entry (or a longer period depending on the defined characteristics of the agents used). * major surgery within 4 weeks of starting the study.

Keywords: poly(adp ribose) polymerases dacarbazine
quality of nursing care during the covid-19 pandemic

Conditions: COVID-19 Pandemic; Children, Only; Hospitalism; Nurse's Role; Feelings

Summary: enabling school-age children to evaluate the care they receive provides feedback on the quality of care by determining children's satisfaction with care, and gives important feedback on the quantity and quality of care. evaluation of nursing care, emotions and behaviors from the perspective of children during the covid-19 pandemic process will guide the improvement of the quality of care. as a result of the literature review on this subject, no research has been found, and it is thought that this research will contribute to the field. this research was conducted to evaluate nursing care and emotions from the perspective of hospitalized children during the covid-19 pandemic process.


Eligibility criteria:
inclusion criteria: * the study included volunteer children who were hospitalized for at least 3 days in the - -- -pediatric clinic, * whose native language was turkish, * between the ages of 8-13, * who did not have any visual, auditory or mental problems, and whose parents gave consent for the study. exclusion criteria: * who fall outside the inclusion criteria
single-dose pk assessment of oral proglumide in those with hepatic impairment

Conditions: Cirrhosis, Liver

Summary: proglumide is an oral cholecystokinin (cck) receptor antagonist that has been shown in non-clinical studies to reverse hepatic fibrosis and decrease the incidence of hepatocellular carcinoma (hcc). because of these potential beneficial properties, proglumide may be useful in decreasing the fibrosis and risk for hcc in those with cirrhosis. although proglumide is safe in those with normal hepatic function, the pharmacokinetics have not been established in those that are hepatic impaired. the purpose of this study is to analyze proglumide blood levels and excretion in subjects with cirrhosis compared to health controls.

the purpose of this study is to measure blood levels of proglumide after a single oral dose (400 mg) over a period of time and compare the blood levels to those with normal hepatic function (n=4) to determine if there is delayed metabolism and clearance of proglumide in those with hepatic impairment (hi) (n=8). eligible subjects will provide a baseline blood and urine sample prior to ingesting proglumide 400 mg po. blood will be collected from an intravenous catheter after ingestion at the following intervals: 1 hr, 3 hrs, 5 hrs, 7 hrs and 24 hr (± 4-5 hours). after 3 hrs and 5 hrs subjects will provide a urine sample. samples will be analyzed by mass spectometry. proglumide blood and urine levels in ng/ml will be plotted over time and the cmax (peak plasma concentration), tmax (time to reach cmax) and t1/2 (elimination half time) calculated for each subject and compared to that of 4 healthy controls.

Eligibility criteria:
inclusion criteria: * cirrhosis previously confirmed by one of the following: liver biopsy, fibroscan, fibrosure, mr-elastography, or nodular liver on radiographic imaging like ct or mri. child-pugh classification a (n=4) and child-pugh classification b (n=4) exclusion criteria: * those that are child-pugh classification c cirrhosis * gastrointestinal bleeding from esophageal varices within 6 months * chronic kidney disease with estimated glomerular filtration rate (egfr of \< 90 ml/min/1.73m2) * hepatic encephalopathy * those that have had an organ transplant * active hepatitis c, active hepatitis b, and those with hiv disease * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners
the proof of concept phase 2 study to evaluate the safety and efficacy of clevudine in patients with mild and moderate covid-19

Conditions: COVID-19

Summary: the purpose of this clinical trial is to assess the safety and efficacy of clevudine 150 mg versus placebo once daily administration with standard of care therapy for 10 days in patients with mild and moderate covid-19.


Eligibility criteria:
key inclusion criteria: 1. over 19 years of age 2. covid-19 confirmed by a real-time rt-pcr tests, and hospitalized 3. patients who experienced first symptom related to covid-19 within 7days prior to enrollment and confirmed 2 or more relative symptoms at the time of randomization. 4. patients with peripheral capillary oxygen saturation(spo2) greater than 94% at the time of screening, who do not need supplemental oxygen therapy. key exclusion criteria: 1. patients who participated in other clinical trials related to covid-19 2. patients who were administered drugs directly to covid-19 24hours prior to the start of the study. 3. patients who need oxygen supply or breathing device (non-invasive mechanical ventilation(via mask)), mechanical ventilator requirement (via endotracheal tube or tracheostomy tube, ecmo requirement) at the time of screening or baseline 4. patients whose ast or alt has increased by more than 5 times the normal lab value.

Keywords: clevudine